Back to search

Ireland· IE-PA-PA23355/039/002

Relifex 1g film-coated tablets

A nabumetone product containing nabumetone, registered in Ireland by Viatris Healthcare Limited. The same ATC class is registered in 14 of our 19 countries.

ATC M01AX01

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedRelifex 1g film-coated tabletsATCM01AX01REGISTER NO.IE-PA-PA23355/039/002PACKS LISTED1CHECKEDSeptember 28, 2026

Where it is registered

Nabumetone is registered in 14 of 19 countries.

Countries holding a registration under ATC M01AX01 (nabumetone), each read from that country’s own register.

  • This record: Ireland, from HPRA (Ireland)
  • 8 of them publish a price we can compare per daily dose

Nabumetone · ATC M01AX01

14 / 19 countries

  • Belgiumprice
  • Canada
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of nabumetone costs, country by country.

Normalised to the WHO defined daily dose (1 g), the median price runs from $0.37 in France to $0.73 in Italy — a ×2.0 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Nabumetone · price per daily dose (1 g)

USD · FX 28 Sept 2026

  • IT Italy$0.73
  • FR France$0.37
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

HPRA (Ireland)
Active substance
Nabumetone
Manufacturer
Viatris Healthcare Limited
Country
Ireland (IE)
ATC code
M01AX01
ATC class
Nabumetone
Defined daily dose
1 g, O
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    PA23355/039/002

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

289 interactions on record for nabumetone.

Graded by severity as the source publishes them — 57 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Nabumetone · interactions on record

289 records

  • 57 severe
  • 142 moderate
  • 4 minor
  • 86 info

Most severe, free to view

  • DicoumarolB01AA01severe
  • WarfarinB01AA03severe
  • DalteparinB01AB04severe
  • EnoxaparinB01AB05severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Nabumetone in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All nabumetone products

Authorised across Europe · EMA

The same active substance is authorised in 17 EEA countries. Names it is sold under:

  • Belgium · Gambaran, Nabumeton Tillomed
  • Germany · Relifex
  • Estonia · Relifex
  • Spain · Relif
  • France · Nabucom
  • United Kingdom (Northern Ireland) · Nabumetone Accord-Uk, Nabumetone Kent Pharma Uk
  • Greece · Akratol, Nabuton
  • Hungary · Relifex
  • Iceland · Relifex
  • Italy · Nabuser
  • Lithuania · Relifex
  • Luxembourg · Gambaran
  • Latvia · Relifex
  • Netherlands · Mebutan, Mebutan Dispers
  • Norway · Relifex
  • Poland · Nabuton Vp
  • Sweden · Relifex

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b400704e-1a1f-44bf-93cd-64bb7b571d2f
GET /v1/drugs/b400704e-1a1f-44bf-93cd-64bb7b571d2f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Film-coated tablet",
  "routes": [
    "Oral use"
  ],
  "source": "hpra",
  "atc_all": [
    "M01AX",
    "M01AX01"
  ],
  "strength": null,
  "pa_number": "PA23355/039/002",
  "substances": [
    "Nabumetone"
  ],
  "legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
  "market_info": "Marketed",
  "authorised_at": "16/10/2009",
  "dispensing_status": "Product subject to prescription which may be renewed (B)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}

See everything about nabumetone.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.